Home Ricerca Sedi Chi siamo Organigramma Personale Contatti Didattica Login Documenti EN
Progetti in evidenza
INCIPIT
(Link esterno)

ISTAPCA
(1209 visite)

Fondo Europeo Pesca
(622 visite)

Euro-BioImaging
(Link esterno)

Fondazione Veronesi
(Link esterno)

LightDyNAmics
(1094 visite)

 INMiND
(1186 visite)

Instruct-IT
(Link esterno)

 PRIN
(1329 visite)

 eHealthNet
(1090 visite)

Ponrec
(1028 visite)

MFAG Grant
(1134 visite)

MERIT
(Link esterno)


Collegamenti

Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]   Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]


Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications (143 visite)

Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S

Head & Neck (ISSN: 1043-3074), 2015; 37(5): 763-770.



Tipo di articolo: Journal Article,

Impact factor: 2.76, Impact factor a 5 anni: 2.79

Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84923165976&partnerID=40&md5=89fab1b27b11d1f8ea1684046db28847

Parole chiave: Akt, P53, Chemoradiotherapy, Epidermal Growth Factor Receptor (egfr), Head And Neck Squamous Cell Carcinoma, Intracellular Pathway, Radioresistance, Adenovirus Vector, Amphiregulin, Bevacizumab, Cetuximab, Contusugene Ladenovec, Cyclin D1, Dactolisib, Docetaxel, Erlotinib, Initiation Factor 4e, K Ras Protein, Lontucirev, Mammalian Target Of Rapamycin, Methotrexate, Perifosine, Phosphatidylinositol 3 Kinase, Protein Bax, Protein Kinase B, Protein P53, Puma Protein, Temsirolimus, Tipifarnib, Transforming Growth Factor, Unindexed Drug, Uvomorulin, Vorinostat, [1 (4 Oxo 8 Phenyl 4h 1 Benzopyran 2 Yl)morpholinio]methoxysuccinylarginylglycylaspartylserine Acetate, Advanced Cancer, Apoptosis, Article, Autophosphorylation, Cancer Radiotherapy, Cancer Recurrence, Cell Migration, Cell Proliferation, Cell Survival, Dna Damage, Dna Repair, Down Regulation, Enzyme Inhibition, Enzyme Phosphorylation, Epithelial Mesenchymal Transition, G1 Phase Cell Cycle Checkpoint, Gene Mutation, Gene Overexpression, Human, Immunohistochemistry, Ionizing Radiation, Papillomavirus Infection, Priority Journal, Radiation Dose Fractionation, Radiosensitivity, Signal Transduction, T Lymphocyte Activation, Upregulation, Viral Gene Therapy, Virus Replication, Wild Type, Egfr Protein, Mtor Protein, Target Of Rapamycin Kinase, Drug Effects, Female, Head And Neck Neoplasms, Molecularly Targeted Therapy, Pathology, Physiology, Procedures, Prognosis, Radiation Response, Risk Assessment, Treatment Outcome, Molecular Targeted Therapy, Radiation Tolerance, Radiotherapy Dosage, Tor Serine-Threonine Kinases,

Affiliazioni:

*** IBB - CNR ***
Head and Neck Medical Oncology Unit, National Tumor Institute of Naples, Naples, Italy.
Institute of Biostructures and Bioimaging, National Council of Research (CNR)Naples Italy
Department of Advanced Biomedical SciencesUniversity Federico IINaples Italy
Department of Clinical Medicine and SurgeryUniversity Federico IINaples Italy
Lester and Sue Smith Breast Center, Baylor College of MedicineHouston Texas
Department of Medical OncologyUniversity of SalernoSalerno Italy



Riferimenti:

Ang, K.K., Andratschke, N.H., Milas, L., Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy (2004) Int J Radiat Oncol Biol Phys, 58, pp. 959-96

(2013), http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, NCCN guidelines. Accessed January 4Pignon, J.P., Le Maître, A., Maillard, E., Bourhis, J., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients (2009) Radiother Oncol, 92, pp. 4-14. , MACH-NC Collaborative Group

Ang, K.K., Berkey, B.A., Tu, X., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma (2002) Cancer Res, 62, pp. 7350-7356

Freudlsperger, C., Burnett, J.R., Friedman, J.A., Kannabiran, V.R., Chen, Z., Van Waes, C., EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: Attractive targets for molecular-oriented therapy (2011) Expert Opin Ther Targets, 15, pp. 63-74

Kumar, R., Hung, M.C., Signaling intricacies take center stage in cancer cells (2005) Cancer Res, 65, pp. 2511-2515

Bussink, J., Van Der Kogel, A.J., Kaanders, J.H., Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer (2008) Lancet Oncol, 9, pp. 288-296

Hama, T., Yuza, Y., Saito, Y., Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma (2009) Oncologist, 14, pp. 900-908

Eriksen, J.G., Steiniche, T., Askaa, J., Alsner, J., Overgaard, J., The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck (2004) Int J Radiat Oncol Biol Phys, 58, pp. 561-566

Zhu, X., Zhang, F., Zhang, W., He, J., Zhao, Y., Chen, X., Prognostic role of epidermal growth factor receptor in head and neck cancer: A meta-analysis (2013) J Surg Oncol, 108, pp. 387-397

Sun, W., Long, G., Wang, J., Mei, Q., Liu, D., Hu, G., Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: A meta-analysis (2013) Head Neck, , [Epub ahead of print]

Hoogsteen, I.J., Marres, H.A., Van Den Hoogen, F.J., Expression of EGFR under tumor hypoxia: Identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistance (2012) Int J Radiat Oncol Biol Phys, 84, pp. 807-814

Saki, M., Toulany, M., Rodemann, H.P., Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells (2013) Radiother Oncol, 108, pp. 473-478

Overgaard, J., Hansen, H.S., Specht, L., Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial (2003) Lancet, 362, pp. 933-940

Corvò, R., Evidence-based radiation oncology in head and neck squamous cell carcinoma (2007) Radiother Oncol, 85, pp. 156-170

Bentzen, S.M., Atasoy, B.M., Daley, F.M., Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial (2005) J Clin Oncol, 23, pp. 5560-5567

Pedicini, P., Nappi, A., Strigari, L., Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (2012) Radiat Oncol, 7, p. 143

Bonner, J.A., Harari, P.M., Giralt, J., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck (2006) N Engl J Med, 354, pp. 567-578

Awada, A., Zhang, S., Gil, T., A phase i clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies (2007) Curr Med Res Opin, 23, pp. 991-1003

Li, S., Takasu, T., Perlman, D.M., Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release (2003) J Biol Chem, 278, pp. 3015-3022

Hong, K.O., Kim, J.H., Hong, J.S., Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells (2009) J Exp Clin Cancer Res, 28, p. 28

Bruzzese, F., Leone, A., Rocco, M., HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT (2011) J Cell Physiol, 226, pp. 2378-2390

Toulany, M., Baumann, M., Rodemann, H.P., Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity (2007) Mol Cancer Res, 5, pp. 863-872

Dent, P., Yacoub, A., Contessa, J., Stress and radiation-induced activation of multiple intracellular signaling pathways (2003) Radiat Res, 159, pp. 283-300

Qiu, W., Schönleben, F., Li, X., PIK3CA mutations in head and neck squamous cell carcinoma (2006) Clin Cancer Res, 12, pp. 1441-1446

Lui, V.W., Hedberg, M.L., Li, H., Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers (2013) Cancer Discov, 3, pp. 761-769

Yoshida, K., Sasaki, R., Nishimura, H., Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer (2010) Head Neck, 32, pp. 646-655

Alshareeda, A.T., Negm, O.H., Albarakati, N., Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer (2013) Breast Cancer Res Treat, 139, pp. 301-310

Groselj, B., Kerr, M., Kiltie, A.E., Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression (2013) Radiother Oncol, 108, pp. 429-433

Kuo, M.L., Chuang, S.E., Lin, M.T., Yang, S.Y., The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6 (2001) Oncogene, 20, pp. 677-685

Zhan, M., Han, Z.C., Phosphatidylinositide 3-kinase/AKT in radiation responses (2004) Histol Histopathol, 19, pp. 915-923

Wymann, M.P., Bulgarelli-Leva, G., Zvelebil, M.J., Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction (1996) Mol Cell Biol, 16, pp. 1722-1733

Vlahos, C.J., Matter, W.F., Hui, K.Y., Brown, R.F., A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) (1994) J Biol Chem, 269, pp. 5241-5248

Garlich, J.R., De, P., Dey, N., A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity (2008) Cancer Res, 68, pp. 206-215

Ma, B.B., Lui, V.W., Hui, C.W., Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models (2014) Cancer Lett, 343, pp. 24-32

Hideshima, T., Catley, L., Yasui, H., Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells (2006) Blood, 107, pp. 4053-4062

Argiris, A., Cohen, E., Karrison, T., A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer (2006) Cancer Biol Ther, 5, pp. 766-770

Bauman, J.E., Arias-Pulido, H., Lee, S.J., A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma (2013) Oral Oncol, 49, pp. 461-467

Bhatt, V.R., Ganti, A.K., Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck (2013) Oral Oncol, 49, p. e25

Brown, C.J., Lain, S., Verma, C.S., Fersht, A.R., Lane, D.P., Awakening guardian angels: Drugging the p53 pathway (2009) Nat Rev Cancer, 9, pp. 862-873

Vousden, K.H., Lu, X., Live or let die: The cell's response to p53 (2002) Nat Rev Cancer, 2, pp. 594-604

Gasco, M., Crook, T., The p53 network in head and neck cancer (2003) Oral Oncol, 39, pp. 222-231

Murphy, M., Ahn, J., Walker, K.K., Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a (1999) Genes Dev, 13, pp. 2490-2501

Mihara, M., Erster, S., Zaika, A., P53 has a direct apoptogenic role at the mitochondria (2003) Mol Cell, 11, pp. 577-590

Yu, J., Zhang, L., PUMA, a potent killer with or without p53 (2008) Oncogene, 271, pp. S71-S83

Somers, K.D., Merrick, M.A., Lopez, M.E., Incognito, L.S., Schechter, G.L., Casey, G., Frequent p53 mutations in head and neck cancer (1992) Cancer Res, 52, pp. 5997-6000

Couture, C., Raybaud-Diogène, H., Têtu, B., P53 and Ki-67 as markers of radioresistance in head and neck carcinoma (2002) Cancer, 94, pp. 713-722

Skinner, H.D., Sandulache, V.C., Ow, T.J., TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence (2012) Clin Cancer Res, 18, pp. 290-300

Poeta, M.L., Manola, J., Goldwasser, M.A., TP53 mutations and survival in squamous-cell carcinoma of the head and neck (2007) N Engl J Med, 357, pp. 2552-2561

Csuka, O., Remenár, E., Koronczay, K., Doleschall, Z., Németh, G., Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer (1997) Pathol Oncol Res, 3, pp. 204-210

Valente, L.J., Gray, D.H., Michalak, E.M., P53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa (2013) Cell Rep, 3, pp. 1339-1345

Yoo, G.H., Moon, J., Leblanc, M., A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: Report of the Southwest Oncology Group (2009) Arch Otolaryngol Head Neck Surg, 135, pp. 869-874

Clayman, G.L., El-Naggar, A.K., Lippman, S.M., Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma (1998) J Clin Oncol, 16, pp. 2221-2232

Nemunaitis, J., Nemunaitis, J., Head and neck cancer: Response to p53-based therapeutics (2011) Head Neck, 33, pp. 131-134

Pearson, S., Jia, H., Kandachi, K., China approves first gene therapy (2004) Nat Biotechnol, 22, pp. 3-4

Tassone, P., Old, M., Teknos, T.N., Pan, Q., P53-based therapeutics for head and neck squamous cell carcinoma (2013) Oral Oncol, 49, pp. 733-737

Nemunaitis, J., Khuri, F., Ganly, I., Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer (2001) J Clin Oncol, 19, pp. 289-298

Ganly, I., Kirn, D., Eckhardt, G., A phase i study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (2000) Clin Cancer Res, 6, pp. 798-806

Yuki, K., Takahashi, A., Ota, I., Sensitization by glycerol for CDDP-therapy against human cultured cancer cells and tumors bearing mutated p53 gene (2004) Apoptosis, 9, pp. 853-859

Ota, I., Okamoto, N., Yane, K., Therapeutic strategies for head and neck cancer based on p53 status (2012) Exp Ther Med, 3, pp. 585-591

Bykov, V.J., Issaeva, N., Shilov, A., Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound (2002) Nat Med, 8, pp. 282-288

Roh, J.L., Kang, S.K., Minn, I., Califano, J.A., Sidransky, D., Koch, W.M., P53-reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma (2011) Oral Oncol, 47, pp. 8-15

Xie, X., Piao, L., Bullock, B.N., Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma (2014) Oncogene, 33, pp. 1037-1046

Smokeless tobacco and some tobacco-specific N-nitrosamines (2007) IARC Monogr Eval Carcinog Risks Hum, 89, pp. 1-592. , Working Group On The Evaluation Of Carcinogenic Risks To Humans I

Park, B.J., Chiosea, S.I., Grandis, J.R., Molecular changes in the multistage pathogenesis of head and neck cancer (2010) Cancer Biomark, 9, pp. 325-339

Lassen, P., Eriksen, J.G., Hamilton-Dutoit, S., Tramm, T., Alsner, J., Overgaard, J., Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck (2009) J Clin Oncol, 27, pp. 1992-1998

Cattani, P., Hohaus, S., Bellacosa, A., Association between cyclin D1 (CCND1) gene amplification and human papillomavirus infection in human laryngeal squamous cell carcinoma (1998) Clin Cancer Res, 4, pp. 2585-2589

Kostareli, E., Holzinger, D., Hess, J., New concepts for translational head and neck oncology: Lessons from HPV-related oropharyngeal squamous cell carcinomas (2012) Front Oncol, 2, p. 36

Licitra, L., Perrone, F., Bossi, P., High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma (2006) J Clin Oncol, 24, pp. 5630-5636

Kofler, B., Laban, S., Busch, C.J., Lörincz, B., Knecht, R., New treatment strategies for HPV-positive head and neck cancer (2014) Eur Arch Otorhinolaryngol, 271, pp. 1861-1867

Pajares, B., Trigo, J.M., Toledo, M.D., Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer (2013) BMC Cancer, 13, p. 26



Head and neck squamous cell carcinoma (HNSCC) is strongly associated with alcohol and tobacco consumption. Lately, the incidence of human papillomavirus (HPV)-related tumors has shown a significant increase, and HPV-related tumors show distinctive features if compared with the HPV-negative counterpart. Locally advanced HNSCC can be treated with concomitant chemoradiotherapy, but early recurrences sometimes occur. Relapses are often related to an intrinsic radioresistance of the tumors. Alterations in intracellular pathways, primarily involved in cell proliferation, apoptosis, and DNA repair, can lead to radioresistance. Preclinical and clinical evidence highlighted that 3 main pathways, including the epidermal growth factor receptor (EGFR), the phosphotidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), and the p53 signaling cascades, play a crucial role in radioresistance development. A future approach may consist in the association of radiotherapy (RT) and selective inhibition of the key pathways involved in radioresistance. Phase I, II, and III clinical trials are currently testing these novel treatment strategies. © 2015 Wiley Periodicals, Inc. Head Neck 37: 763-770, 2015 © 2015 Wiley Periodicals, Inc.
Nessun risultato.
Nessun risultato.

Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]   Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]


Perri F, Ionna F, Muto P, Marzo MD, Caponigro F, Longo F, Vittoria Scarpati GD, Lorenzo GD, Giuliano M, Solla R
* Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy (2 visite)
N/D (ISSN: 2056-5623linking), 2018 Oct 26; 5(1): FSO347-FSO347.
Impact Factor: 0
Dettagli    Esporta in BibTeX    Esporta in EndNote

Perri F, Longo F, Della Vittoria Scarpati G, Pisconti S, Longo V, Addeo R, Carducci F, Buonerba C, Fulciniti F, Solla R
* Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment (101 visite)
Clin Case Rep (ISSN: 2050-0904print, 2050-0904linking), 2017 Nov 24; 6(1): 56-62.
Impact Factor: 0.54
Dettagli    Esporta in BibTeX    Esporta in EndNote

Cella L, D'Avino V, Palma G, Conson M, Liuzzi R, Picardi M, Pressello MC, Boboc GI, Battistini R, Donato V, Pacelli R
* Modeling the risk of radiation-induced lung fibrosis: Irradiated heart tissue is as important as irradiated lung (151 visite) (PDF 118 visite)
Radiother Oncol (ISSN: 1879-0887electronic, 0167-8140linking), 2015 Aug 12; 117(1): 36-43.
Impact Factor: 4.817
Dettagli    Esporta in BibTeX    Esporta in EndNote

Cella L, Oh JH, Deasy JO, Palma G, Liuzzi R, D'Avino V, Conson M, Picardi M, Salvatore M, Pacelli R
* Predicting radiation-induced valvular heart damage (133 visite)
Acta Oncol (ISSN: 0284-186xlinking), 2015 Mar 24; 54(10): 1796-1804.
Impact Factor: 3.73
Dettagli    Esporta in BibTeX    Esporta in EndNote

Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, Kim Y, Bastos-Carvalho A, Orlandi A, Ambati J, Ruvo M, Bianco R, de Falco S
* Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models (127 visite)
Oncotarget (ISSN: 1949-2553, 1949-2553electronic, 1949-2553linking), 2015; 6(12): 10563-10576.
Impact Factor: 5.008
Dettagli    Esporta in BibTeX    Esporta in EndNote

Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Greco A, Gramanzini M, Ortosecco G, Fonti R, Brunetti A, Del Vecchio S
* Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Using 3 '-Deoxy-3 '-[F-18]-Fluorothymidine Positron Emission Tomography (185 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2014 Sep 15; 20(18): 4806-4815.
Impact Factor: 8.722
Dettagli    Esporta in BibTeX    Esporta in EndNote

D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
* A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients (111 visite)
International Journal Of Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Impact Factor: 5.085
Dettagli    Esporta in BibTeX    Esporta in EndNote

Galdiero S, Falanga A, Vitiello M, Grieco P, Caraglia M, Morelli G, Galdiero M
* Exploitation of viral properties for intracellular delivery (135 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2014 Jul; 20(7): 468-478.
Impact Factor: 1.546
Dettagli    Esporta in BibTeX    Esporta in EndNote

Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, Laterza MM, Ruol A, Fabozzi A, Napolitano V, Iovino F, Lieto E, Fei L, Conzo G, Ciardiello F, De Vita F
* Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study (1644 visite)
Curr Oncol Multimed Inc (ISSN: 1198-0052), 2014 Jun; 21(3): 125-133.
Impact Factor: 1.785
Dettagli    Esporta in BibTeX    Esporta in EndNote

Cella L, Liuzzi R, D'Avino V, Conson M, Di Biase A, Picardi M, Pugliese N, Solla R, Salvatore M, Pacelli R
* Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury (121 visite)
Acta Oncol Acta Oncologica (ISSN: 0284-186x, 1651-226x), 2014 May; 53(5): 613-619.
Impact Factor: 2.997
Dettagli    Esporta in BibTeX    Esporta in EndNote

Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani BM, Parsons SJ, De Placido S, Bianco R
* Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models (142 visite)
Breast Cancer Res Biomed Central Ltd (ISSN: 1465-5411), 2014; 16(3): R45-R45.
Impact Factor: 0.635
Dettagli    Esporta in BibTeX    Esporta in EndNote

Perri F, Dell'Oca I, Muto P, Schiavone C, Aversa C, Fulciniti F, Solla R, Scarpati GD, Buonerba C, Di Lorenzo G, Caponigro F
* Optimal management of a patient with recurrent nasopharyngeal carcinoma (87 visite)
World Journal Of Clinical Cases (ISSN: 2307-8960), 2014; 2(7): 297-300.
Impact Factor: 0.895
Dettagli    Esporta in BibTeX    Esporta in EndNote

Pedicini P, Fiorentino A, Improta G, Nappi A, Salvatore M, Storto G
* Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma (125 visite)
Clin Transl Oncol (ISSN: 1699-048x), 2013 Nov; 15(11): 919-924.
Impact Factor: 1.6
Dettagli    Esporta in BibTeX    Esporta in EndNote

Cella L, Liuzzi R, Conson M, D'Avino V, Salvatore M, Pacelli R
* Multivariate normal tissue complication probability modeling of heart valve dysfunction in Hodgkin lymphoma survivors (151 visite)
Int J Radiat Oncol Biol Phys (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2013 Oct 1; 87(2): 304-310.
Impact Factor: 4.176
Dettagli    Esporta in BibTeX    Esporta in EndNote

Nande R, Greco A, Gossman MS, Lopez JP, Claudio L, Salvatore M, Brunetti A, Denvir J, Howard CM, Claudio PP
* Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer (151 visite)
Current Gene Therapy (ISSN: 1875-5631, 1566-5232), 2013 Jun 1; 13(3): 163-174.
Impact Factor: 4.906
Dettagli    Esporta in BibTeX    Esporta in EndNote

Lombardo B, Rocco T, Esposito MT, Cantilena B, Gargiulo S, Greco A, Montanaro D, Brunetti A, Pastore L
* Thymidine Kinase-Mediated Shut Down of Bone Morphogenetic Protein-4 Expression Allows Regulated Bone Production (123 visite)
Current Gene Therapy (ISSN: 1566-5232, 1875-5631), 2013 Jun 1; 13(3): 202-210.
Impact Factor: 4.906
Dettagli    Esporta in BibTeX    Esporta in EndNote

 Cella L, Conson M, Liuzzi R, Pacelli R
* In regard to boomsma et al (153 visite)
Int J Radiat Oncol Biol Phys (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2013 Jan 1; 85(1): 11-11.
Impact Factor: 4.176
Dettagli    Esporta in BibTeX    Esporta in EndNote

Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marf G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R
* Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models (145 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2013 Jan 1; 19(1): 138-147.
Impact Factor: 8.193
Dettagli    Esporta in BibTeX    Esporta in EndNote

Cella L, Liuzzi R, Conson M, D'Avino V, Salvatore M, Pacelli R
* Development of multivariate NTCP models for radiation-induced hypothyroidism: A comparative analysis (155 visite) (PDF 132 visite)
Radiat Oncol Radiation Oncology (ISSN: 1748-717x), 2012 Dec 27; 7(1): 224-224.
Impact Factor: 2.107
Dettagli    Esporta in BibTeX    Esporta in EndNote

Pedicini P, Nappi A, Strigari L, Jereczek-Fossa BA, Alterio D, Cremonesi M, Botta F, Vischioni B, Caivano R, Fiorentino A, Improta G, Storto G, Benassi M, Orecchia R, Salvatore M
* Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (100 visite)
Radiation Oncology (ISSN: 1748-717x), 2012 Sep 24; 7: 143-143.
Impact Factor: 2.107
Dettagli    Esporta in BibTeX    Esporta in EndNote

Cella L, Conson M, Caterino M, De Rosa N, Liuzzi R, Picardi M, Grimaldi F, Solla R, Farella A, Salvatore M, Pacelli R
* Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin's lymphoma (163 visite) (PDF 132 visite)
Int J Radiat Oncol Biol Phys (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2012 Apr 1; 82(5): 1802-1808.
Impact Factor: 4.524
Dettagli    Esporta in BibTeX    Esporta in EndNote

Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer (237 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
Dettagli    Esporta in BibTeX    Esporta in EndNote

Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer (175 visite)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
Dettagli    Esporta in BibTeX    Esporta in EndNote

Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (157 visite)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
Dettagli    Esporta in BibTeX    Esporta in EndNote

Diana D, Basile A, De Rosa L, Di Stasi R, Auriemma S, Arra C, Pedone C, Turco MC, Fattorusso R, D'Andrea LD
* Beta-Hairpin Peptide That Targets Vascular Endothelial Growth Factor (vegf) Receptors: Design, Nmr Characterization, And Biological Activity (161 visite)
J Biol Chem Journal Of Biological Chemistry (ISSN: 1083-351x, 0021-9258), 2011 Dec 2; 286(48): 41680-41691.
Impact Factor: 4.773
Dettagli    Esporta in BibTeX    Esporta in EndNote

Cella L, Liuzzi R, Conson M, Torre G, Caterino M, De Rosa N, Picardi M, Camera L, Solla R, Farella A, Salvatore M, Pacelli R
* Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin's lymphoma (122 visite)
Radiother Oncol (ISSN: 0167-8140, 1879-0887, 1879-0887electronic), 2011 Nov; 101(2): 316-321.
Impact Factor: 5.58
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Morisco A, Tesauro D, Pedone C, Morelli G
* Naposomes: A new class of peptide-derivatized, target-selective multimodal nanoparticles for imaging and therapeutic applications (181 visite)
Ther Deliv (ISSN: 2041-5990), 2011 Feb; 2(2): 235-257.
Impact Factor: 0
Dettagli    Esporta in BibTeX    Esporta in EndNote

Ciccarelli M, Sorriento D, Cipolletta E, Santulli G, Fusco A, Zhou R-H, Eckhart AD, Peppel K, Koch WJ, Trimarco B, Iaccarino G
* Impaired neoangiogenesis in β2-adrenoceptor gene-deficient mice: Restoration by intravascular human β2-adrenoceptor gene transfer and role of NFkB and CREB transcription factors (113 visite)
Br J Pharmacol British Journal Of Pharmacology (ISSN: 0007-1188), 2011; 162(3): 712-721.
Impact Factor: 4.409
Dettagli    Esporta in BibTeX    Esporta in EndNote

Orditura M, Galizia G, Napolitano V, Martinelli E, Pacelli R, Lieto E, Aurilio G, Vecchione L, Morgillo F, Catalano G, Ciardiello F, Del Genio A, Di Martino N, De Vita F
* Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study (103 visite)
Cancer Investigation (ISSN: 0735-7907), 2010 Oct; 28(8): 820-827.
Impact Factor: 2.39
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M
* PET/CT in cancer research: From preclinical to clinical applications (172 visite)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Impact Factor: 4.02
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Vecchio S, Zannetti A, Iommelli F, Lettieri A, Brunetti A, Salvatore M
* Molecular imaging of tumor microenvironment (113 visite)
Q J Nucl Med Mol Imaging (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2010 Jun; 54(3): 243-258.
Impact Factor: 1.724
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Vecchio S, Zannetti A, Iommelli F, Lettieri A, Brunetti A, Salvatore M
* Molecular imaging of tumor microenvironment: Challenges and perspectives (175 visite)
Q J Nucl Med Mol Imaging (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2010 Jun; 54(3): 249-258.
Impact Factor: 1.724
Dettagli    Esporta in BibTeX    Esporta in EndNote

Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P
* Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death (108 visite)
J Biol Chem Journal Of Biological Chemistry (ISSN: 0021-9258, 1083-351x), 2010 Feb 26; 285(9): 6563-6572.
Impact Factor: 5.328
Dettagli    Esporta in BibTeX    Esporta in EndNote

Sorriento D, Santulli G, Fusco A, Anastasio A, Trimarco B, Iaccarino G
* Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-κB-Dependent hypertrophic gene expression (88 visite)
Hypertensionhypertension (ISSN: 0194-911x), 2010; 56(4): 696-704.
Impact Factor: 6.908
Dettagli    Esporta in BibTeX    Esporta in EndNote

D'Andrea LD, Del Gatto A, De Rosa L, Romanelli A, Pedone C
* Peptides targeting angiogenesis related growth factor receptors (13888 visite)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1873-4286, 1381-6128), 2009 Jul; 15(21): 2414-2429.
Impact Factor: 4.414
Dettagli    Esporta in BibTeX    Esporta in EndNote

Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D'Armiento MR, De Placido S
* Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: A phase II study (120 visite)
Annals Of Oncology (ISSN: 0923-7534), 2009 May; 20(5): 906-912.
Impact Factor: 5.647
Dettagli    Esporta in BibTeX    Esporta in EndNote

Storto G, Nicolai E, Salvatore M
* [18F]FDG-PET-CT for early monitoring of tumor response: When and why (145 visite)
Q J Nucl Med Mol Imaging (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2009 Apr; 53(2): 167-180.
Impact Factor: 1.724
Dettagli    Esporta in BibTeX    Esporta in EndNote

Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Del Vecchio L, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M
* MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma (149 visite)
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2009 Mar 24; 4(3): e4998-e4998.
Impact Factor: 4.351
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Lettieri A, Salvatore M
* Molecular imaging of drug resistance in cancer (114 visite)
Minerva Biotecnol (ISSN: 1120-4826), 2009 Mar; 21(1): 31-36.
Impact Factor: 0.268
Dettagli    Esporta in BibTeX    Esporta in EndNote

Sorriento D, Campanile A, Santulli G, Leggiero E, Pastore L, Trimarco B, Iaccarino G
* A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFκB activity (110 visite)
Mol Cancermolecular Cancer (ISSN: 1476-4598), 2009; 8: N/D-N/D.
Impact Factor: 4.16
Dettagli    Esporta in BibTeX    Esporta in EndNote

Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Pirozzi G, Bianco R, Tortora G, Salvatore M, Del Vecchio S
* Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type (168 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2008 Aug 15; 14(16): 5209-5219.
Impact Factor: 6.488
Dettagli    Esporta in BibTeX    Esporta in EndNote

Zannetti A, Fonti R, Iommelli F, Papaccioli A, Sommella J, Tortora G, Bianco R, Salvatore M, Del Vecchio S
* SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer (129 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Oct; 34: 277-309.
Impact Factor: 4.101
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (194 visite)
Q J Nucl Med Mol Imaging (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
Dettagli    Esporta in BibTeX    Esporta in EndNote

Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L
* Cetuximab is an active treatment of metastatic and chemorefractory thymoma (92 visite)
Frontiers In Bioscience (ISSN: 1093-9946, 1093-4715), 2007 Jan 1; 12(2): 757-761.
Impact Factor: 2.989
Dettagli    Esporta in BibTeX    Esporta in EndNote

D'Andrea LD, Del Gatto A, Pedone C, Benedetti E
* Peptide-based molecules in angiogenesis (154 visite)
Chem Biol Drug Des Chemical Biology And Drug Design (ISSN: 1747-0277, 1747-0285), 2006 Feb; 67(2): 115-126.
Impact Factor: 2.507
Dettagli    Esporta in BibTeX    Esporta in EndNote

Cittadini A, Monti MG, Iaccarino G, Di Rella F, Tsichlis PN, Di Gianni A, Strömer H, Sorriento D, Peschle C, Trimarco B, Saccà L, Condorelli G
* Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling (122 visite)
Gene Ther Gene Therapy (ISSN: 0969-7128, 0969-7128linking), 2006; 13(1): 8-19.
Impact Factor: 4.782
Dettagli    Esporta in BibTeX    Esporta in EndNote

Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, Paudice A, Elia A, Santulli G, Campanile A, Arcucci O, Pastore L, Salvatore F, Condorelli G, Trimarco B
* AKT participates in endothelial dysfunction in hypertension (96 visite)
Circulationcirculation (ISSN: 0009-7322), 2004; 109(21): 2587-2593.
Impact Factor: 12.563
Dettagli    Esporta in BibTeX    Esporta in EndNote

Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M, Fusco A
* ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells (144 visite)
J Clin Endocrinol Metab Journal Of Clinical Endocrinology And Metabolism (ISSN: 0021-972x), 2003 Oct 1; 88(10): 5027-5032.
Impact Factor: 5.873
Dettagli    Esporta in BibTeX    Esporta in EndNote



48 Records (45 escludendo Abstract e Conferenze).
Impact factor totale: 184.507 (177.414 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 184.12 (176.676 escludendo Abstract e Conferenze).







    Esporta in BibTeX    Esporta in EndNote

Ultima modifica di Marco Comerci in data Tuesday 15 September 2015, 14:12:14
143 visite. Ultima visita in data Friday 28 December 2018, 16:28:07

Webmaster and developer: Marco Comerci
Per problemi e suggerimenti: adminibb.cnr.it
Ultimo aggiornamento: Tuesday 19 February 2019, 11:31:13